Home
>
National Drug Code (NDC)
>
TARCEVA
TARCEVA - 50242-064-01 - (erlotinib hydrochloride)
Drug Information of TARCEVA
| Product NDC: | 50242-064 |
| Proprietary Name: | TARCEVA |
| Non Proprietary Name: | erlotinib hydrochloride |
| Active Ingredient(s): | 150 mg/1 & nbsp; erlotinib hydrochloride |
| Administration Route(s): | ORAL |
| Dosage Form(s): | TABLET |
| Coding System: | National Drug Codes(NDC) |
Labeler Information of TARCEVA
| Product NDC: | 50242-064 |
| Labeler Name: | Genentech, Inc. |
| Product Type: | HUMAN PRESCRIPTION DRUG |
| FDA Application Number: | NDA021743 |
| Marketing Category: | NDA |
| Start Marketing Date: | 20050430 |
Package Information of TARCEVA
| Package NDC: | 50242-064-01 |
| Package Description: | 30 TABLET in 1 BOTTLE (50242-064-01) |
NDC Information of TARCEVA
| NDC Code | 50242-064-01 |
| Proprietary Name | TARCEVA |
| Package Description | 30 TABLET in 1 BOTTLE (50242-064-01) |
| Product NDC | 50242-064 |
| Product Type Name | HUMAN PRESCRIPTION DRUG |
| Non Proprietary Name | erlotinib hydrochloride |
| Dosage Form Name | TABLET |
| Route Name | ORAL |
| Start Marketing Date | 20050430 |
| Marketing Category Name | NDA |
| Labeler Name | Genentech, Inc. |
| Substance Name | ERLOTINIB HYDROCHLORIDE |
| Strength Number | 150 |
| Strength Unit | mg/1 |
| Pharmaceutical Classes | Kinase Inhibitor [EPC],Protein Kinase Inhibitors [MoA] |
